Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication

dc.contributor.authorLi, Guiyun
dc.contributor.authorChen, Nanhai
dc.contributor.authorFeng, Zehua
dc.contributor.authorBuller, R Mark L
dc.contributor.authorOsborne, John
dc.contributor.authorHarms, Tiara
dc.contributor.authorDamon, Inger
dc.contributor.authorUpton, Chris
dc.contributor.authorEsteban, David J
dc.date.accessioned2014-08-08T18:36:12Z
dc.date.available2014-08-08T18:36:12Z
dc.date.copyright2006en_US
dc.date.issued2006-10-25
dc.descriptionBioMed Centralen_US
dc.description.abstractBackground: Vaccinia virus (VACV)-DUKE was isolated from a lesion on a 54 year old female who presented to a doctor at the Duke University Medical Center. She was diagnosed with progressive vaccinia and treated with vaccinia immune globulin. The availability of the VACV-DUKE genome sequence permits a first time genomic comparison of a VACV isolate associated with a smallpox vaccine complication with the sequence of culture-derived clonal isolates of the Dryvax vaccine. Results: This study showed that VACV-DUKE is most similar to VACV-ACAM2000 and CLONE3, two VACV clones isolated from the Dryvax® vaccine stock confirming VACV-DUKE as an isolate from Dryvax®. However, VACV-DUKE is unique because it is, to date, the only Dryvax® clone isolated from a patient experiencing a vaccine-associated complication. The 199,960 bp VACV-DUKE genome encodes 225 open reading frames, including 178 intact genes and 47 gene fragments. Between VACV-DUKE and the other Dryvax® isolates, the major genomic differences are in fragmentation of the ankyrin-like, and kelch-like genes, presence of a full-length Interferon- α/β receptor gene, and the absence of a duplication of 12 ORFs in the inverted terminal repeat. Excluding this region, the DNA sequence of VACV-DUKE differs from the other two Dryvax® isolates by less than 0.4%. DNA sequencing also indicated that there was little heterogeneity in the sample, supporting the hypothesis that virus from an individual lesion is clonal in origin despite the fact that the vaccine is a mixed population. Conclusion: Virus in lesions that result from progressive vaccinia following vaccination with Dryvax are likely clonal in origin. The genomic sequence of VACV-DUKE is overall very similar to that of Dryvax® cell culture-derived clonal isolates. Furthermore, with the sequences of multiple clones from Dryvax® we can begin to appreciate the diversity of the viral population in the smallpox vaccinen_US
dc.description.reviewstatusRevieweden_US
dc.description.scholarlevelFacultyen_US
dc.description.sponsorshipThis work was funded through two grants: NIAID/DARPA U01 AI48653-02 (R. M. L. B. and C.U.), Canadian NSERC grant OPG0155125-01 (C.U.).en_US
dc.identifier.citationLi et al. Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication. Virology Journal 2006, 3:88en_US
dc.identifier.urihttp://www.virologyj.com/content/3/1/88
dc.identifier.urihttp://dx.doi.org/10.1186/1743-422X-3-88
dc.identifier.urihttp://hdl.handle.net/1828/5538
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.subject.departmentDepartment of Biochemistry and Microbiology
dc.titleGenomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complicationen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Li_Guiyun_VirolJ_2006.pdf
Size:
655.12 KB
Format:
Adobe Portable Document Format
Description:
Li_Guiyun_VirolJ_2006.pdf
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.74 KB
Format:
Item-specific license agreed upon to submission
Description: